middle.news
Actinogen Raises $17M to Drive Alzheimer’s Trial After Positive Interim Results
10:24am on Monday 2nd of February, 2026 AEDT
•
Healthcare
Read Story
Actinogen Raises $17M to Drive Alzheimer’s Trial After Positive Interim Results
10:24am on Monday 2nd of February, 2026 AEDT
Key Points
Raised $12 million via share placement at $0.042 per share
Additional $5 million targeted through share purchase plan
Funding supports completion of XanaMIA Phase 2b/3 trial and open-label extension
Positive interim analysis materially de-risks trial ahead of November 2026 topline results
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACTINOGEN MEDICAL (ASX:ACW)
OPEN ARTICLE